Summary
Over 3 million Americans live with sHTG, including around 1 million high-risk patients with triglycerides ≥880 mg/dL or ≥500 mg/dL plus a history of acute pancreatitis or other comorbidities.
In June 2026, the FDA approved Ionis’ TRYNGOLZA (already approved for FCS in 2024) as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with sHTG.
The TRYNGOLZA approval was based on the data from the Phase 3 CORE and CORE2 trials.
Key companies such as ArrowHead Pharmaceutical (Plozasiran), 89bio (Pegozafermin), NorthSea Therapeutics (SEFA-1024), and others are evaluating their respective candidates, wh...
